Ignite Creation Date:
2024-05-05 @ 7:16 PM
Last Modification Date:
2024-10-26 @ 9:46 AM
Study NCT ID:
NCT00639522
Status:
UNKNOWN
Last Update Posted:
2009-04-15
First Post:
2008-03-14
Brief Title:
Dose Escalation Study of Liposomal Paclitaxel WithWithout Capecitabine in Patients With Advanced Gastric Carcinoma
Sponsor:
Nanjing Sike Pharmaceutical Co Ltd
Organization:
Nanjing Sike Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel WithWithout Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma
Status:
UNKNOWN
Status Verified Date:
2009-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel withwithout capecitabine in Chinese cancer patients with advanced gastric carcinoma
Detailed Description:
The maximum tolerated dose MTD and pharmacokinetics of a new formulation of taxane liposomal paclitaxel have never been studied in Chinese cancer patients either alone or with capecitabine This clinical trial is designed to find out the MTD and pharmacokinetics of liposomal paclitaxel with a beginning dose of 175mgm2 withwithout Capecitabine in Chinese patients with advanced gastric carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None